<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864042</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-818-103</org_study_id>
    <secondary_id>C4221003</secondary_id>
    <nct_id>NCT03864042</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors</brief_title>
  <official_title>An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and
      multiple oral doses of encorafenib in combination with binimetinib on the single oral dose
      pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme probe substrates using a probe
      cocktail, on an organic anion-transporting polypeptide/breast cancer resistance protein
      (OATP/BCRP) substrate using rosuvastatin and on a CYP2B6 substrate using bupropion. The
      effect of multiple oral doses of the moderate cytochrome P450 (CYP) inhibitor modafinil on
      encorafenib in combination with binimetinib will also be assessed. The study will have 2
      treatment phases, a drug-drug interaction (DDI) phase followed by a post-DDI phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">August 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probe substrate peak plasma concentration (Cmax) in Arms 1 and 2</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Probe substrate concentration from time zero to the time of last quantifiable concentration (AUClast) in Arms 1 and 2</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the amount of probe eliminated via urine over an 8-hour period (Ae0-8) in Arm 1</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in plasma encorafenib and LHY746 Cmax and area under the concentration time curve (AUC) in Arm 3.</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio (MRAUC) for 1-OH midazolam/midazolam, paraxanthine/caffeine, 5-hydroxy omeprazole/omeprazole, hydroxybupropion/bupropion and LHY746/encorafenib</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio (MRCmax) for 1-OH midazolam/midazolam, paraxanthine/caffeine, 5-hydroxy omeprazole/omeprazole, hydroxybupropion/bupropion and LHY746/encorafenib</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ration (MRAe0-8) for E-3174/losartan and dextrorphan/dextromethorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (time to reach Cmax [Tmax]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC from time zero extrapolated to infinity [AUCinf]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (percent of AUC extrapolated [AUC%extrap]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (apparent terminal elimination half-life [T1/2]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (apparent terminal elimination rate constant [Kel]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (apparent total body clearance after extravascular administration [CL/F]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (apparent total volume of distribution after extravascular administration [Vz/F]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (urine concentration [Curine]) for losartan, E-3174, dextromethorphan and dextrorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day-7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (quantity of urine excreted during each collection interval) for losartan, E-3174, dextromethorphan and dextrorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (cumulative amount excreted in urine during each collection interval [CumA]e) for losartan, E-3174, dextromethorphan and dextrorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (percentage of dose recovered in urine [Fe] %) for losartan, E-3174, dextromethorphan and dextrorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUClast) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUCinf,) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC%extrap) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Kel) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (T1/2) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (CL/F) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Vz/F) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUClast) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUCinf,) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC%extrap) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Kel) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (CL/F) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (T1/2) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Vz/F) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by monitoring adverse events (AEs)</measure>
    <time_frame>From first dose of study intervention/treatment until the end of DDI phase (through 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single oral dose of the CYP Probe Cocktail on Day -7, Day 1, and Day 14:
25 mg losartan oral tablet
30 mg (2 x 15 mg) dextromethorphan oral capsule
50 mg caffeine 20 mg/mL oral liquid
20 mg omeprazole oral capsule
2 mg midazolam 2 mg/mL oral syrup
encorafenib/binimetinib continuous daily dosing starting Day 1:
450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)
45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)
All drugs will be taken within 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single oral dose of rosuvastatin and bupropion once on Day -7, Day 1 and Day 14:
10 mg rosuvastatin oral tablet
75 mg bupropion immediate release (IR) oral tablet
encorafenib/binimetinib continuous daily dosing starting Day 1:
450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)
45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)
All drugs will be taken within 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will begin encorafenib/binimetinib continuous daily dosing starting Day 1:
450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)
45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)
then receive continuous treatment of modafinil on Day 15 through Day 21:
- 400 mg (2 × 200 mg) modafinil tablet once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dextromethorphan</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion immediate release (IR)</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>encorafenib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
    <arm_group_label>Arm 3 - Modafinil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>binimetinib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
    <arm_group_label>Arm 3 - Modafinil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 3 - Modafinil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria - Patients must meet all of the inclusion criteria to be eligible
        for enrollment into the study:

          -  Histologically confirmed diagnosis of locally advanced, unresectable or metastatic
             cutaneous melanoma or unknown primary melanoma American Joint Committee on Cancer
             (AJCC) Stage IIIB, IIIC or IV; or other BRAF V600-mutant advanced solid tumors

          -  Presence of BRAF V600E and/or V600K mutation in tumor tissue prior to enrollment, as
             determined using a local test;

          -  Evidence of measurable or non-measurable lesions

          -  Patient with unresectable locally advanced or metastatic melanoma who has received no
             prior treatment or progressed on or after prior systemic therapy; Note: Prior therapy
             with a BRAF proto-oncogene serine-threonine protein kinase (BRAF) inhibitor and/or a
             mitogen-activated protein (MAP) kinase (MEK) inhibitor is permitted except in the
             regimen immediately prior to study entry

          -  Patient with other (non-melanoma) BRAF V600E and/or V600K -mutant advanced solid
             tumors who has progressed on standard therapy or for whom there are no available
             standard therapies; Note: Prior therapy with a BRAF inhibitor and/or a MEK inhibitor
             is permitted except in the regimen immediately prior to study entry

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Adequate bone marrow, hepatic and renal function as specified in the protocol

          -  ARM 1 ONLY: Non-smoker who has not used nicotine containing products for at least 3
             months prior to the first dose.

        Key Exclusion Criteria - Patients meeting any of the following criteria are not eligible
        for enrollment in the study:

          -  Symptomatic brain metastasis. Patients previously treated or untreated for these
             conditions that are asymptomatic in the absence of corticosteroid and anti-epileptic
             therapy are allowed. Brain metastases must be stable, with imaging (e.g., magnetic
             resonance imaging [MRI] or computed tomography [CT] demonstrating no current evidence
             of progressive brain metastases at screening);

          -  Symptomatic or untreated leptomeningeal disease;

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity
             or hypercoagulability syndromes);

          -  Clinically significant cardiac disease

          -  Known hyper-coagulability risks other than malignancy (e.g., Factor V Leiden
             syndrome);

          -  Thromboembolic event except catheter-related venous thrombosis ≤ 12 weeks prior to
             starting study treatment.

          -  Discontinuation of prior BRAF and/or MEK inhibitor treatment due to left ventricular
             dysfunction, pneumonitis/interstitial lung disease, or retinal vein occlusion;

          -  ARM 1 ONLY: Positive urine cotinine test at screening

          -  ARM 3 ONLY:

               -  History of psychosis, depression or mania;

               -  History of angioedema;

               -  History of mitral valve prolapse;

               -  History of left ventricular hypertrophy;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Compassionate Care Research Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UIC University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Montréal</city>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Montréal</city>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>El Palmar</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <keyword>melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

